• Zum Hauptinhalt springen
  • Zum Footer springen
  • Deutsch - de
  • English - en

    Comprehensiv...

    • Clinical research
      • Interdisciplinary pediatric study center (Hauner iPSC)
      • Ped-COVID-19 Study
      • Michael Albert
      • Scivias Study
      • TRACE Study
      • ImmGenDC Study
      • Hematology/Oncology/Coagulation
    • Research Labs
      • Binder Lab
      • Bohlen Lab
      • Braun Lab
      • Gaertner Lab
      • Griese Lab
      • Hauck Lab
      • Hübner Lab
      • Jeremias lab
      • Kim-Hellmuth Lab
      • Klein Lab
      • Koletzko Lab
      • Kotlarz Lab
      • Lange-Sperandio Lab
      • von Mutius Lab
      • Nußbaum Lab
      • Rosenecker Lab
      • Schaub Lab
      • Schmid Lab
      • Schwerd Lab
    • PhD Program
    • Technology platforms
      • Bioinformatics
      • Flow Cytometry
      • High throughput sequencing
      • Microscopy
      • Pre-GMP Facility
      • Mass spectrometry
      • Hauner Biobank
      • Organoid Lab
      • Humangenetik am Hauner
    • News/Events
      • News
      • Rare Disease Day
      • ECHO-Meeting
      • Meinhard von Pfaundler-Lectures
      • Klaus Betke Symposium
    • Join us!
    1. CCRC-HaunerEN
    2. Research Labs
    3. Braun Lab

    Braun Lab

    Max Eder Junior Research Group

    • Research topics

      • Targeted therapy for childhood cancers
      • Genome-wide genetic screens
      • Role of RNA life cycle in cancer biology
      • Personalized therapy of pediatric tumors


      Dr. med. Christian J. Braun

      ✉ chr.braun@med.lmu.de

      ☎ +49-89-4400-54724

    • Our mission - precision oncology for children with cancer

      Every child is unique – and so is every cancer! This means that a treatment that successfully works for one little patient may not be effective for another. It is our mission to better understand the complicated molecular processes specific to each individual tumor – and to exploit this knowledge for the development of molecularly targeted and fully personalized treatment approaches.   

      Synthetic sickness - and why we believe "super cancers" don't exist

      Synthetic lethality is a concept in molecular oncology that exploits the vulnerabilities of cancer cells while sparing normal cells. It's as easy as that!

      We are driven by the idea that while cancer cells are "fitter" than most other cells of the human body, the complicated rewiring of biochemical processes that drives proliferation, therapeutic resistance or metastasis also renders them "addicted" to druggable processes. This concept is not new and has been exploited by doctors since the 1940s: Chemotherapy harms quickly dividing tumor cells more than many other body cells.

      It is our mission to bring this to a new level and define molecular cancer vulnerabilities. Instead of administering highly toxic chemotherapeutics, we develop therapeutic approaches that interfere precisely with a molecular signaling pathways a specific tumor is addicted to.

      We prefer the term "synthetic sickness" - because we do not neccesarily require that a new molecular approach must kill tumor cells. Reducing their "fitness" is oftentimes enough. But that's just the fineprint. 

      Harnessing the power of CRISPR genome editing

      We employ cutting edge CRISPR technologies to decipher and therapeutically exploit molecular addictions of cancer cells. CRISPR genome editing was a real game changer for our work and enabled us to systematically probe whether a specific tumor cell is addicted to the function of a certain gene. We used to do this gene by gene – which is long, costly and slow. To speed up our discovery process, we now employ CRISPR screens to do this in parallel for thousands of genes and within a couple of days. These experiment cannot only be performed in plastic dishes, but also in organoid models or even in living tissues. 

      Drugging aberrant transcription and RNA metabolism

      We have a special interest drugging transcription and RNA metabolism. Such processes are frequently aberrant in cancer, oftentimes druggable with small molecules and right at the heart of cancer biology! Our favorite molecular target is PRMT5 – an enzyme that regulates a specific splicing program centered around intron biology. PRMT5 was the top hit of one of our screens (Cancer Cell, 2017), several clinical trials have since been launched for cancer patients.


    • Dr. med. Christian Braun

      Group Leader

      ✉ chr.braun@med.lmu.de

      ☎ 089-4400-54724

      Room: K0.05

      Andres Carbonell


      Andres Carbonell Adames, M. Sc.

      Doctoral Researcher (PhD track)

      M.Sc. LMU Munich, B. Sc. Penn State, U.S..A

      ✉ Andres.Carbonell@med.uni-muenchen.de

      ☎ 089-4400-54724, Room: K0.31

      Copyright 2024. Alle Rechte vorbehalten.


      Melina Bäuerle, M. Sc.

      Doctoral Researcher (PhD track)

      M.Sc. LMU Munich

      ✉ Melina.Baeuerle@med.uni-muenchen.de

      ☎ 089-4400-54724, Room: K0.31

      Stephan Beissner


      Eva Bergmann, M. Sc.

      Doctoral Researcher (PhD track)

      M.Sc. LMU Munich

      ✉ Eva.Bergmann@med.uni-muenchen.de

      ☎ 089-4400-54724, Room: K0.31


      Annika Danker, Cand. med.

      Doctoral Researcher (MD track)

      ✉ Annika.Danker@med.uni-muenchen.de

      ☎ 089-4400-54724, Room: K0.31


      Daniel Schäfer, Cand. med.

      Doctoral Researcher (MD track)

      Jointly supervised with Kimberly Stegmaier
      at Dana-Farber Cancer Institute / Harvard Medical School

      Moritz Schanzer


      Moritz Schanzer, Cand. med.

      Doctoral Researcher (MD track)

      ✉ moritz.schanzer@med.uni-muenchen.de

      ☎ 089-4400-54724, Room: K0.31


      Stephan Beissner


      Heidi Noll-Puchta, VTA

      Technician & Lab Manager

      ✉ Heidi.Noll-Puchta@med.uni-muenchen.de

      ☎ 089-4400-54724

      Room: K0.31

      Copyright unknown


      Mark Rassner, 

      Dr. med. Dipl.-Mol.med.

      Clinician Scientist 

      ✉ Mark.Rassner@med.uni-muenchen.de

      ☎ 089-4400-54724, Room: K0.31

      Stephan Beissner


      Dr. med. Robert Lersch

      Clinician Scientist 

      ✉ Robert.Lersch@med.uni-muenchen.de

      ☎ 089-4400-54724, Room: K0.31


      Liana Gahleitner, Cand. med.

      Doctoral Researcher (MD track)

      ✉ Liana.Gahleitner@med.uni-muenchen.de

      ☎ 089-4400-54724, Room: K0.31


      Dorothea Mock, Cand. med.

      Doctoral Researcher (MD track)

      ✉ dorothea.mock@med.uni-muenchen.de

      ☎ 089-4400-54724, Room: K0.31

      Mayra Lenz


      Mayra Lenz, Cand. med.

      Doctoral Researcher (MD track)

      ✉ mayra.lenz@med.uni-muenchen.de

      ☎ 089-4400-54724, Room: K0.31

      Copyright unknown


      Emilie von Poblotzki, Cand. med.

      Doctoral Researcher (MD track)

      ✉ Emilie.Poblotzki@med.uni-muenchen.de

      ☎ 089-4400-54724, Room: K0.31

      Alumni


      John Ku, B. Sc. 

      Master Thesis Student

      B. Sc. California State Polytechnic University, USA 




      Satyendra Kumar, PhD

      Postdoctoral Researcher

      PhD Karolinska Institute, Sweden



    • Selected Publications

      C. J. Braun*, A. C. Adames, D. Saur & R. Rad*. Tutorial: design and execution of CRISPR in vivo screens. *Co-corresponding

      Nature protocols (2022)
      Journal Impact Factor2021: 17.021     

                  >> Selected "Paper of the month" by LMU's medical faculty    Link

      DOI

      T. Kaltenbacher, J. Loprich, R. Maresch, J. Weber, S. Muller, R. Oellinger, N. Gross, J. Griger, N. de Andrade Kratzig, P. Avramopoulos, D. Ramanujam, S. Brummer, S. A. Widholz, S. Barthel, C. Falcomata, A. Pfaus, A. Alnatsha, J. Mayerle, M. Schmidt-Supprian, M. Reichert, G. Schneider, U. Ehmer, C. J. Braun, D. Saur, S. Engelhardt, and R. Rad. CRISPR somatic genome engineering and cancer modeling in the mouse pancreas and liver.

      Nature protocols (2022)
      Journal Impact Factor2021: 17.021

      DOI

      J. Weber, C. J. Braun, D. Saur, R. Rad. In vivo functional screening for systems-level integrative cancer genomics. In vivo functional screening for systems-level integrative cancer genomics.

      Nature Reviews Cancer (2020)
      Journal Impact Factor2021: 69.800

      DOI

      M. Becker, H. Noll-Puchta, D. Amend, F. Nolte, C. Fuchs, I. Jeremias*, C. J. Braun*. CLUE: a bioinformatic and wet-lab pipeline for multiplexed cloning of custom sgRNA libraries.

      Nucleic Acids Research (2020)
      Journal Impact Factor2021: 19.160

      DOI

      C. J. Braun*, M. Stanciu*, P. L. Boutz*, J. C. Patterson, D. Calligaris, F. Higuchi, R. Neupane, S. Fenoglio, D. P. Cahill, H. Wakimoto, N. Y. R. Agar, M. B. Yaffe, P. A. Sharp, M. T. Hemann, J. A. Lees. Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma. *equal contributions

      Cancer Cell (2017)

      Journal Impact Factor2021: 38.585

      DOI

      C. J. Braun*, P. M. Bruno*, M. A. Horlbeck, L. A. Gilbert, J. S. Weissman, M. T. Hemann. Versatile in vivo regulation of tumor phenotypes by dCas9 mediated transcriptional perturbation. *equal contributions

      PNAS (2016)

      Journal Impact Factor2021: 10.700

      DOI

      I. G. Cannell, K. A. Merrick*, S. Morandell*, C. Z. Zhu, C. J. Braun, R. A. Grant, E. R. Cameron, M. Tsao, M.T. Hemann and M. B. Yaffe. A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-defective Tumors to Chemotherapy.

      Cancer Cell (2015)

      Journal Impact Factor2021: 38.585

      DOI

      C. J. Braun*, K. Boztug*, A. Paruzynski*, M. Witzel*, A. Schwarzer, M. Rothe, U. Modlich, R. Beier, G. Göhring, D. Steinemann, R. Fronza, C. R. Ball, R. Haemmerle, S. Naundorf, K. Kühlcke, M. Rose, C. Fraser, L. Mathias, R. Ferrari, M. R. Abboud, W. Al-Herz, I. Kondratenko, L. Maródi, H. Glimm, B. Schlegelberger, A. Schambach, M. H. Albert, M. Schmidt, C. von Kalle, and C. Klein. Gene Therapy for Wiskott-Aldrich Syndrome--long-term efficacy and genotoxicity. *equal contributions

      Science translational medicine (2014)

      Journal Impact Factor2021: 19.359

      DOI

      C. P. Pallasch, I. Leskov, C. J. Braun, D. Vorholt, A. Drake, Y. M. Soto-Feliciano, E. H. Bent, J. Schwamb, B. Iliopoulou, N. Kutsch, N. van Rooijen, L. P. Frenzel, C. M. Wendtner, L. Heukamp, K. A. Kreuzer, M. Hallek, J. Chen, and M. T. Hemann. Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy.

      Cell (2014)

      Journal Impact Factor2021: 66.850

      DOI
      All publications Braun Lab
    • CLUE: Multiplexed sgRNA library design and production

      Pooled sgRNA libraries targeting hundreds or thousands of individual genes are right at the heart of functional genomics. Such libraries are broadly available, but usually not tailored to the scientific interest of researchers. With our tool CRISPR clue were were out to bring custom sgRNA library production to all labs - streamlining the cloning process, lowering synthesis costs and reducing bioinformatics to the bare minimum. Check out www.crispr-clue.de and the manuscript at Nucleic Acids Research (NAR)! 

      Update February 28th 2024: CLUE is under maintenance, but will be back soon! 

      Andres' podcasts

      Andres is very passionate about making science & molecular biology accessible to the general public. Check out his podcasts!

      Youtube
      Spotify
    • JOIN OUR TEAM

      Join us!

      We are highly enthusiastic about science - but also love to teach, discuss, collaborate and hang out.

      If you are interested in CRISPR screens, functional genomics, genetic crosstalk, context dependence, translation into clinic and the discovery of new treatment opportunities for childhood cancers: please don't hesitate to send an email to Christian (chr.braun@med.lmu.de) or any of the current lab members. 

    • Christian Braun Lab


      Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital,

      Klinikum der Universität München, LMU München


      Postal Address: Lindwurmstr. 4

      Visiting Address: Research Building, Lindwurmstraße 2a

      80337 Munich

      Germany


      Room: K 0.5

      Phone: +49 (0)89 - 4400 - 54724

      Fax: +49 (0)89 - 4400 - 57702

      Email: chr.braun@med.lmu.de


      Lab Manager: Heidi Noll-Puchta

      Postal Address: Lindwurmstr. 4

      Visiting Address: Research Building, Lindwurmstraße 2a

      80337 Munich

      Germany


      Room: K 0.31

      Phone: +49 (0)89 - 4400 - 54724

      Fax: +49 (0)89 - 4400 - 57702

      Email: Heidi.Noll-Puchta@med.uni-muenchen.de

    Research at CCRC Hauner

    Contact LMU Klinikum

    Contact CCRC Hauner

    Haunersches

    CCRC Hauner - Comprehensive Childhood Research Center

    Kinderklinik und Kinderpoliklinik

    im Dr. von Haunerschen Kinderspital

    Ludwig Maximilians Universität München

    Lindwurmstr. 4

    80337 Munich, Germany


    Editor login
    Imprint | Data-Safety